Unichem Signs A Near Two-Decade Truce On Sleeping Disorder Drug Sunosi
Other Patent Infringement Actions Continue In New Jersey; Potential For $500m Brand
Executive Summary
Unichem has bowed to Axsome Therapeutics’ IP portfolio and strategy, signing a settlement agreement that will keep the Indian firm’s US generic version of Sunosi from the market until the beginning of the 2040s.